<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03807973</url>
  </required_header>
  <id_info>
    <org_study_id>R18-179</org_study_id>
    <nct_id>NCT03807973</nct_id>
  </id_info>
  <brief_title>Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.</brief_title>
  <official_title>Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will use brain PET/MRI and an investigational radioactive drug called [Zr-89]oxine
      to track the location of white blood cells (also called leukocytes) in the body. PET/MRI will
      be used to visualize labeled white blood cells and determine if they enter the central
      nervous system in conditions associated with brain inflammation (also called
      neuroinflammation). By better understanding the roleneuroinflammation in fibromyalgia,
      chronic fatigue syndrome, and multiple sclerosis, the investigator hopes to be able to better
      diagnose and treat patients in the future.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 30, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Regional brain distribution of radiolabeled white blood cells</measure>
    <time_frame>3 years</time_frame>
    <description>Descriptive statistics (means and standard deviations) of standardized uptake values (SUVs) will be presented for the patient groups and healthy controls in the following regions: whole brain, gray matter, white matter, atlas-based regions of interest, and lesions (MS patients only). Normality of the SUV distribution will be tested using Shapiro-Wilk tests, and the data will be transformed to normal distribution if necessary.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Fibromyalgia</condition>
  <condition>Chronic Fatigue Syndrome</condition>
  <condition>Multiple Sclerosis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic Fatigue Syndrome</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[Zr-89]Oxine-labeled leukocytes PET/MR</intervention_name>
    <description>All study participants will undergo an investigational imaging study using autologous [Zr-89]-lableled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocutes in the blood sample will be isolated for labeling using [Zr-89]oxine. The labeled leukocutes (7.4- 18.5 MBq, 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.</description>
    <arm_group_label>Chronic Fatigue Syndrome</arm_group_label>
    <arm_group_label>Fibromyalgia</arm_group_label>
    <arm_group_label>Healthy Controls</arm_group_label>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18 to 65 years of age 2.Healthy volunteer OR

          -  Clinical diagnosis of Multiple Sclerosis (MS) OR

          -  Meets 2016 American College of Rheumatology (ACR) case definition criteria for
             fibromyalgia OR

          -  Meets 1994 Fukuda case definition criteria for Chronic Fatigue Syndrome

        Exclusion Criteria:

          1. Contraindication to MRI

          2. Pregnancy

          3. Lactation

          4. Individuals who are unable to participate in the imaging portion due to severity of
             their medical condition

          5. Chronic infectious disease (e.g. HIV, HCV)

          6. Viral or bacterial illness requiring medical attention and/or antibiotics within 1
             month of study participation

          7. Diagnosis of cancer, including leukemia

          8. Blood or blood clotting disorder

          9. Except for individuals with MS, a diagnosis of autoimmune disease is exclusionary

         10. Positive urine Î²-hCG test day of procedure or a serum hCG test within 48 hours prior
             to the administration of [89Zr]Oxinate-4-labeled leukocytes

         11. Currently enrolled in a clinical trial utilizing experimental therapies

         12. Contraindication to gadolinium based contrast agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jonathan McConathy, MD, PhD</last_name>
    <phone>205-996-7115</phone>
    <email>jmcconathy@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>April Riddle, BSRT</last_name>
    <phone>205-934-6504</phone>
    <email>ariddle@uabmc.edu</email>
  </overall_contact_backup>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>January 14, 2019</study_first_submitted>
  <study_first_submitted_qc>January 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 17, 2019</study_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Jonathan E McConathy</investigator_full_name>
    <investigator_title>MD, PhD, Director for the Division Molecular Imaging and Therapeutics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue Syndrome, Chronic</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

